AstraZeneca Plc’s new drug Imjudo won approval in Japan for two different cancer types when added to the blockbuster medicine Imfinzi, widening the immune therapy’s reach.
The treatment, a monoclonal antibody, is now authorized for forms of lung and liver cancer in Japan for patients who are also receiving Imfinzi, Astra said Wednesday.
The approval, coming after clearance in the US and a positive recommendation in Europe, is another step forward in Chief Executive Officer Pascal Soriot’s effort to deepen the UK drugmaker’s presence in the cancer field.
Read More: Astra Looks to More Than Double New Cancer ...
To read the full article log in.
Read Full Story: https://news.google.com/__i/rss/rd/articles/CBMidGh0dHBzOi8vbmV3cy5ibG9vbWJlc...
BRENTWOOD, Tenn. (WSMV) - A Tennessee doctor has pleaded guilty to committing millions of dollars’ worth of Medicare fraud through her Brentwood optometry practice. Helen Boerman, 48, pleaded guilt...